Terms: = Breast cancer AND KMT2C, ENSG00000055609, MLL3, 58508 AND Treatment
14 results:
1. Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2-positive patients undergoing neoadjuvant therapy: A single-institution retrospective cohort.
Xiong M; Wang X; Liu D; Xiu B; Zhang Q; Chi W; Goh CW; Zhang L; Chen M; Ren H; Shao ZM; Yang B; Wu J
Cancer Med; 2024 Jan; 13(2):e6955. PubMed ID: 38379328
[TBL] [Abstract] [Full Text] [Related]
2. Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer.
Han Y; Wang J; Sun T; Ouyang Q; Li J; Yuan J; Xu B
Signal Transduct Target Ther; 2023 Nov; 8(1):429. PubMed ID: 37973901
[TBL] [Abstract] [Full Text] [Related]
3. Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer.
Park YH; Im SA; Park K; Wen J; Lee KH; Choi YL; Lee WC; Min A; Bonato V; Park S; Ram S; Lee DW; Kim JY; Lee SK; Lee WW; Lee J; Kim M; Kim HS; Weinrich SL; Ryu HS; Kim TY; Dann S; Kim YJ; Fernandez DR; Koh J; Wang S; Park SY; Deng S; Powell E; Ravi RK; Bienkowska J; Rejto PA; Park WY; Kan Z
Genome Med; 2023 Jul; 15(1):55. PubMed ID: 37475004
[TBL] [Abstract] [Full Text] [Related]
4. Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.
Miyashita M; Bell JSK; Wenric S; Karaesmen E; Rhead B; Kase M; Kaneva K; De La Vega FM; Zheng Y; Yoshimatsu TF; Khramtsova G; Liu F; Zhao F; Howard FM; Nanda R; Beaubier N; White KP; Huo D; Olopade OI
Breast Cancer Res; 2023 May; 25(1):58. PubMed ID: 37231433
[TBL] [Abstract] [Full Text] [Related]
5. mll3 is a de novo cause of endocrine therapy resistance.
Stauffer KM; Elion DL; Cook RS; Stricker T
Cancer Med; 2021 Nov; 10(21):7692-7711. PubMed ID: 34581028
[TBL] [Abstract] [Full Text] [Related]
6. mll3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant breast cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway.
Wu HT; Liu YE; Hsu KW; Wang YF; Chan YC; Chen Y; Chen DR
Am J Chin Med; 2020; 48(5):1221-1241. PubMed ID: 32668964
[TBL] [Abstract] [Full Text] [Related]
7. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
Kim SS; Lee MH; Lee MO
Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
[TBL] [Abstract] [Full Text] [Related]
8. Association between histone lysine methyltransferase kmt2c mutation and clinicopathological factors in breast cancer.
Chen X; Zhang G; Chen B; Wang Y; Guo L; Cao L; Ren C; Wen L; Liao N
Biomed Pharmacother; 2019 Aug; 116():108997. PubMed ID: 31146111
[TBL] [Abstract] [Full Text] [Related]
9. Revealing clonality and subclonality of driver genes for clinical survival benefits in breast cancer.
Lan Y; Zhao E; Luo S; Xiao Y; Li X; Cheng S
Breast Cancer Res Treat; 2019 May; 175(1):91-104. PubMed ID: 30739230
[TBL] [Abstract] [Full Text] [Related]
10. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic breast cancer Patients with Multiline Resistance.
Hu ZY; Xie N; Tian C; Yang X; Liu L; Li J; Xiao H; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Xiao M; Tang Y; He Q; Chang L; Xia X; Yi X; Liao Q; Ouyang Q
EBioMedicine; 2018 Jun; 32():111-118. PubMed ID: 29807833
[TBL] [Abstract] [Full Text] [Related]
11. EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients.
Zhang L; Liu Y; Wang M; Wu Z; Li N; Zhang J; Yang C
J Mol Cell Biol; 2017 Dec; 9(6):477-488. PubMed ID: 29272522
[TBL] [Abstract] [Full Text] [Related]
12. Analysis of Paired Primary-Metastatic Hormone-Receptor Positive breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance.
Manso L; Mourón S; Tress M; Gómez-López G; Morente M; Ciruelos E; Rubio-Camarillo M; Rodriguez-Peralto JL; Pujana MA; Pisano DG; Quintela-Fandino M
PLoS One; 2016; 11(5):e0155840. PubMed ID: 27195705
[TBL] [Abstract] [Full Text] [Related]
13. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.
Katoh M
Epigenomics; 2016 Feb; 8(2):285-305. PubMed ID: 26411517
[TBL] [Abstract] [Full Text] [Related]
14. Whole-genome analysis informs breast cancer response to aromatase inhibition.
Ellis MJ; Ding L; Shen D; Luo J; Suman VJ; Wallis JW; Van Tine BA; Hoog J; Goiffon RJ; Goldstein TC; Ng S; Lin L; Crowder R; Snider J; Ballman K; Weber J; Chen K; Koboldt DC; Kandoth C; Schierding WS; McMichael JF; Miller CA; Lu C; Harris CC; McLellan MD; Wendl MC; DeSchryver K; Allred DC; Esserman L; Unzeitig G; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Leitch M; Hunt K; Olson J; Tao Y; Maher CA; Fulton LL; Fulton RS; Harrison M; Oberkfell B; Du F; Demeter R; Vickery TL; Elhammali A; Piwnica-Worms H; McDonald S; Watson M; Dooling DJ; Ota D; Chang LW; Bose R; Ley TJ; Piwnica-Worms D; Stuart JM; Wilson RK; Mardis ER
Nature; 2012 Jun; 486(7403):353-60. PubMed ID: 22722193
[TBL] [Abstract] [Full Text] [Related]
